Brief: Oxford BioMedica Expects FY 2026 Revenues Between £180 Mln and £200 Mln
BRIEF-Oxford BioMedica Expects FY 2026 Revenues Between £180 Mln and £200 Mln Aug 7 (Reuters) - Oxford BioMedica PLC OXB.L:
OXFORD BIOMEDICA PLC - HALF YEAR TRADING UPDATE AND NOTICE OF RESULTS
OXFORD BIOMEDICA PLC: UPDATED FY 2026 GUIDANCE REFLECTS IMPACT OF SHORT-TERM SHIFT IN CLIENT ORDERING BEHAVIOUR
OXFORD BIOMEDICA - FY 2026 EBITDA MARGIN EXPECTED MID-SINGLE-DIGIT PERCENT EXCLUDING ONE-OFF COSTS
OXFORD BIOMEDICA - FY 2026 REVENUES NOW EXPECTED TO BE £180-£200 MILLION
OXFORD BIOMEDICA PLC: FY 2026 REVENUES NOW EXPECTED TO BE £180-200 MILLION
OXFORD BIOMEDICA - FY 2027 REVENUE GROWTH GUIDANCE REMAINS 25-30% YEAR-ON-YEAR
OXFORD BIOMEDICA - FY 2027 PROFITABILITY EXPECTED TO IMPROVE WITH AT LEAST DOUBLE-DIGIT PERCENT EBITDA MARGINS
OXFORD BIOMEDICA PLC: CONTINUED AMBITION TO ACHIEVE REVENUES OF C.£500M IN 2030
Source text: ID:nRSG7486Pa
Further company coverage: OXB.L
((Reuters.Briefs@thomsonreuters.com;;))